PMGC Holdings (ELAB) Operating Leases (2022 - 2025)

PMGC Holdings (ELAB) posted Operating Leases of $972843.0 for Q4 2025, up 3561.3% sequentially from $26571.0 in Q1 2024.

PMGC Holdings (ELAB) Operating Leases (2022 - 2025) Analysis & Trends

PMGC Holdings has reported Operating Leases for 4 years, with the latest figure at $972843.0 in Q4 2025.

Quarterly Operating Leases changed N/A year-over-year to $972843.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $972843.0 (changed N/A YoY) and the FY2025 annual result came in at $972843.0, changed N/A from the prior year.
Operating Leases improved to $972843.0 in Q4 2025 per ELAB's latest filing, from $26571.0 in the prior quarter.
Over five years, Operating Leases peaked at $103.3 million in Q3 2023 and troughed at $26571.0 in Q1 2024.
A 4-year average of $20.9 million and a median of $172601.0 in 2022 frame the typical range for Operating Leases.
The widest YoY moves for Operating Leases: up 62.06% in 2023, down 62.06% in 2023.
Over 4 years, Operating Leases stood at $172601.0 in 2022, then plunged by 62.06% to $65489.0 in 2023, then sank by 59.43% to $26571.0 in 2024, then jumped by 3561.3% to $972843.0 in 2025.
According to Business Quant data, Operating Leases over the past three periods registered $972843.0, $26571.0, and $65489.0 for Q4 2025, Q1 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	PMGC Holdings	3.01 Mn	-15.78 Mn	385,691.00

Download Data